Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Avidity Biosciences Inc RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs... see more

Recent & Breaking News (NDAQ:RNA)

Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights

GlobeNewswire 6 days ago

Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

PR Newswire December 1, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

PR Newswire December 1, 2025

Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights

GlobeNewswire November 22, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX

PR Newswire November 21, 2025

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

PR Newswire November 19, 2025

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

PR Newswire November 10, 2025

Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights

PR Newswire November 7, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE - WTRG), Cadence Bank (NYSE - CADE), Avidity Biosciences, Inc. (Nasdaq - RNA), Plymouth Industrial REIT, Inc. (NYSE - PLYM)

GlobeNewswire November 6, 2025

Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights

PR Newswire October 30, 2025

Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

PR Newswire October 28, 2025

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Business Wire October 28, 2025

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Business Wire October 27, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)

PR Newswire October 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE - WTRG), Cadence Bank (NYSE - CADE), Avidity Biosciences, Inc. (Nasdaq - RNA), Plymouth Industrial REIT, Inc. (NYSE - PLYM)

GlobeNewswire October 27, 2025

HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

PR Newswire October 27, 2025

RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS

GlobeNewswire October 26, 2025

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

PR Newswire October 26, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference

PR Newswire October 16, 2025

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

PR Newswire October 13, 2025